Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Myocardial Blood Flow Reserve
Interventions
Regadenoson, Rubidium-82
Drug · Radiation
Lead sponsor
Timothy M. Bateman, MD
Industry
Eligibility
40 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Coronary Disease
Interventions
Myocardial contrast echocardiography, Stress echocardiography with dobutamine
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Coronary Artery Disease
Interventions
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Drug
Lead sponsor
MedTrace Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more
Terminated Not applicable Interventional Results available

SHIELD II Clinical Investigation

NCT02468778
Conditions
Coronary Artery Disease
Interventions
HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 43 more
Conditions
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions
Supira System
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sacramento, California • Atlanta, Georgia • New York, New York + 1 more
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Plano, Texas
Enrolling by invitation No phase listed Observational

Serial PET MPI in Patients Undergoing Cancer Treatment

NCT05913999
Conditions
Cancer, Chemotherapeutic Toxicity, Coronary Artery Disease, Coronary Microvascular Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Results available

PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR

NCT05349084
Conditions
Coronary Artery Disease
Interventions
PET-cCTA-cFFR
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 4 Interventional Accepts healthy volunteers

3D PET Myocardial Blood Flow and Rb82 Infusion Profiles

NCT05286593
Conditions
Normal Healthy Volunteers Without Chronic Medical Conditions, Coronary Artery Disease, Cardiac Risk Factors, Myocardial Infarction
Interventions
Slow Infusion of Rubidium-82
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Coronary Artery Disease
Interventions
RespirAct
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Coronary Artery Disease, Acute Myocardial Infarction, Acute Myocardial Infarction of Anterior Wall, Collateral Circulation, Any Site
Interventions
Wellens Sign
Other
Lead sponsor
Coney Island Hospital, Brooklyn, NY
Other
Eligibility
18 Years to 89 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Myocardial Ischemia
Interventions
Timi3 Transthoracic ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Conditions
Circulatory Shock, Cardiovascular Shock
Interventions
Nitroglycerin Topical Product
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Kawasaki Disease, Heart Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
12 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Coronary Artery Disease
Interventions
Percutaneous Mechanical Circulatory Support
Device
Lead sponsor
Kardion Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Chandler, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Conditions
Cardiovascular Disease, Coronary Artery Disease
Interventions
Heart Rate Variability (HRV) Biofeedback (BF), Mental Stress Protocol
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
Cardiogenic Shock
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 4 Interventional Results available

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486
Conditions
Coronary Artery Disease, Type 1 Diabetes Mellitus
Interventions
Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Myocardial Ischemia, Coronary Disease, Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions
Myocardial Perfusion Imaging Study, AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]
Diagnostic Test · Drug
Lead sponsor
Ionetix Corporation
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Miami, Florida • Miami Beach, Florida • Jenkintown, Pennsylvania + 2 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

NCT02589977
Conditions
Heart Failure, Diastolic, Diastolic Heart Failure, Hypertension
Interventions
regadenoson
Drug
Lead sponsor
Marvin W. Kronenberg, M.D.
Other
Eligibility
50 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Type 2 Diabetes
Interventions
Rosiglitazone, Glyburide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Toledo, Ohio